Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Schistosoma mansoni | Thioredoxin glutathione reductase | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | glutathione reductase | 0.0046 | 0.2288 | 0.3241 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0116 | 0.7665 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0046 | 0.2288 | 0.3241 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0116 | 0.7665 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0016 | 0 | 0.5 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0108 | 0.706 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0046 | 0.2288 | 0.3241 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0016 | 0 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0046 | 0.2288 | 0.3241 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0108 | 0.706 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0046 | 0.2335 | 0.3307 |
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0016 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0104 | 0.6774 | 0.8837 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0016 | 0 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0046 | 0.2288 | 0.3241 |
Brugia malayi | glutathione reductase | 0.0046 | 0.2288 | 0.3241 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0108 | 0.706 | 1 |
Leishmania major | trypanothione reductase | 0.0046 | 0.2288 | 0.3241 |
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Schistosoma mansoni | NADP-specific isocitrate dehydrogenase | 0.0108 | 0.706 | 0.706 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0046 | 0.2288 | 0.3241 |
Plasmodium vivax | glutathione reductase, putative | 0.0046 | 0.2288 | 0.3241 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0108 | 0.706 | 1 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0108 | 0.706 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0104 | 0.6774 | 0.8837 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0046 | 0.2288 | 0.2985 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0104 | 0.6774 | 0.8837 |
Treponema pallidum | NADH oxidase | 0.0016 | 0 | 0.5 |
Brugia malayi | Isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0016 | 0 | 0.5 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0108 | 0.706 | 1 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0116 | 0.7665 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0046 | 0.2335 | 0.3307 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0016 | 0 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0016 | 0 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0016 | 0 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0116 | 0.7665 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0016 | 0 | 0.5 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0104 | 0.6774 | 0.8837 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0108 | 0.706 | 0.9211 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0104 | 0.6774 | 0.8837 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0046 | 0.2288 | 0.3241 |
Mycobacterium tuberculosis | Probable reductase | 0.0104 | 0.6774 | 0.8837 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0108 | 0.706 | 1 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0108 | 0.706 | 1 |
Brugia malayi | isocitrate dehydrogenase | 0.0108 | 0.706 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.